Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

SOTC Analytics says it, “strives to report medical intelligence pertaining to neurodegenerative & neurodevelopmental disorders to include Alzheimer's Disease, Parkinson's Disease, Rett Syndrome, Angelman Syndrome, Fragile X, and more” but all it does is cover Anavex. What about the dozens of other companies competing in the space and the many competing technologies? Funny how none of them are ever mentioned. It’s covering Anavex only and only in the most positive light. SOTC never questions or criticizes anything Anavex does.

As far as my “agenda” goes I only have one, which is to make outsized returns on my investment in a high-risk sector. The only hope for Anavex is to get rid of our incompetent CEO and bring on a CEO with deep drug development and commercialization experience, a track record of success, and credibility with influential investors and potential pharma partners. Missling has failed miserably on all fronts but especially when it comes to shareholder value.

I guess defending Missling to the death is more important to you and some others here than making a spectacular return on your investment and seeing a promising therapy reach the market if approval is warranted.

DOG bless,